Ceribell is Catalyzing a Paradigm Shift in Acute Neurological Care and Neurodiagnostics with State-of-the-Art AI-Powered EEG Solutions

Ceribell is leading the charge in revolutionizing seizure management in acute care with its innovative AI-powered point-of-care EEG diagnostic system. The company's mission is focused on making EEG diagnostics widely accessible, efficient, and cost-effective, ultimately enhancing the detection and treatment of neurological conditions.

The Ceribell system provides healthcare providers with rapid access to precise diagnostic information and continuous bedside monitoring 24/7, facilitating accurate patient care and improving hospital-wide efficiencies. Since receiving FDA 510(k) clearance in 2017, the system has been commercially available in the United States. Ceribell's latest advancement, the ClarityPro™ AI algorithm, stands as the first FDA-approved software for diagnosing Electrographic Status Epilepticus, with approval for New Technology Add-on Payment by the U.S. Centers for Medicare and Medicaid Services.

Revolutionizing Neurodiagnostics with AI-Powered Platform

Ceribell's Point-of-Care EEG system stands at the forefront of neurodiagnostics, offering rapid bedside diagnosis and real-time monitoring powered by artificial intelligence (AI). This innovative platform enables early detection and effective management of suspected seizure patients, promoting precise patient care and enhancing hospital-wide efficiencies.

The Ceribell EEG System is meticulously designed to streamline EEG setup, requiring only minutes and minimal training. Its continuous AI monitoring and alert capabilities at the bedside, particularly for status epilepticus, ensure prompt intervention. Additionally, remote access to real-time EEG information further enhances accessibility and flexibility for healthcare providers.

FDA-Cleared Headbands for All Ages: Ceribell's headbands, FDA-cleared for all ages, guarantee safety and versatility in neurodiagnostic applications, facilitating seamless monitoring across diverse patient populations.

24/7 EEG Monitoring and Alerts for Status Epilepticus: Ceribell offers continuous EEG monitoring and alerts for electrographic status epilepticus, commonly known as non-convulsive status epilepticus (NCSE). Its FDA-cleared instantaneous bedside alert system provides crucial early indications of suspected status epilepticus, allowing healthcare providers to intervene promptly.

Real-Time EEG Data Streaming: The Ceribell EEG Portal provides real-time streaming of EEG data to a secure cloud portal, enabling physicians to review EEG information from anywhere. This HIPAA-compliant platform ensures accessibility without compromising patient data security.

Equivalent Signal Quality to Conventional EEG: Ceribell's EEG system ensures signal quality equivalent to conventional EEG, maintaining accuracy throughout the recording process. This reliability improves EEG reading efficiency, facilitating timely and accurate diagnosis.

First FDA-Cleared Seizure Burden Trend: Ceribell introduces the first FDA-cleared seizure burden trend, offering valuable insights into the effectiveness of medications and overall seizure management. This trend assists healthcare providers in assessing treatment efficacy and adjusting interventions accordingly.

Transforming Neurologic Acute Care with AI-Enhanced Monitoring

Ceribell introduces a revolutionary AI-enhanced monitoring solution for neurologic acute care patients, powered by the ClarityPro™ AI algorithm. This innovative technology interprets EEG signals in real-time, providing bedside alerts and continuous monitoring specifically designed for detecting status epilepticus.

ClarityPro™ AI: Transforming EEG Interpretation

At the heart of Ceribell's solution lies the ClarityPro™ AI algorithm, a machine learning tool that interprets EEG signals with unparalleled accuracy. By analyzing EEG data every 10 seconds across all channels, ClarityPro™ estimates seizure burden, providing vital information for timely intervention.

Continuous Bedside Monitoring and Alerts

Ceribell's system, integrated with ClarityPro™ AI, offers 24/7 bedside EEG monitoring and alerts, ensuring prompt detection of status epilepticus. Notably, it boasts the distinction of being the first FDA-cleared instantaneous bedside alert system for diagnosing electrographic status epilepticus, empowering healthcare providers with crucial insights at the point of care.

Remote Monitoring and Medication Effectiveness Assessment

Beyond bedside monitoring, ClarityPro™ provides remote capabilities, including the first FDA-cleared seizure burden display with pre-annotations. This feature supports efficient EEG interpretation and accurate labeling of EEG seizure burden. Additionally, real-time medication effectiveness monitoring enables swift treatment optimization based on patient response.

How ClarityPro™ Works

Trained on thousands of EEGs annotated by epileptologist experts, ClarityPro™ continuously improves its performance. It automatically detects suspected status epilepticus, diagnoses electrographic status epilepticus, and monitors ongoing seizure burden. Clinically proven to match or surpass the performance of neurologists in detecting or ruling out status epilepticus, ClarityPro™ delivers clinically meaningful insights for acute patient management.

Practical Considerations

While EEG provides valuable diagnostic information, clinical decisions should consider multiple factors, including patient history and presentation. Inter-rater variability in EEG interpretation is acknowledged, but ClarityPro™ AI, trained on expert input, offers reliable results. Furthermore, its accuracy continually improves with additional training on a growing dataset.

Designed for Acute Care

ClarityPro™ AI focuses on measuring the overall burden of seizures rather than detailed labeling of individual events. This acute care tool prioritizes the cumulative impact of seizure activity, enhancing patient management and prognosis in acute care settings.

Jane Chao, PhD, CEO & Co-Founder, Ceribell

Jane Chao, the co-founder and CEO of Ceribell, holds a Ph.D. in biophysics from Cornell University. Before she joined Ceribell, Jane had a solid history of leadership and success in business. She launched her career as a management consultant with McKinsey & Company, and later made her move into the medical space joining Novartis as their Senior Strategy Manager. She then enjoyed a successful career at Genentech as their Principal Manager of Portfolio Management Strategy. In 2015, Jane started Ceribell full-time as the CEO, the position she currently holds. She has built and led the Ceribell team from early concept stages to a fully commercial, FDA-cleared, clinically proven, and highly successful commercial product that is changing the standard of care for critically ill patients.

Ceribell is leading the industry with the first FDA 510(k) clearances for digital seizure detection algorithm and multiple FDA Breakthrough Designations.